SAN DIEGO, CA--(Marketwire - November 08, 2011) - Medistem Inc. (PINKSHEETS: MEDS) announced today the appointment of Dr. Hugh S. Taylor to its Scientific Advisory Board. Dr. Taylor is the first scientist to identify the bone marrow origin of endometrial tissue, and performed independent experiments demonstrating that endometrial stem cells are capable of treating diabetes and Parkinson's Disease in animal models.
Dr. Taylor is Professor of Obstetrics, Gynecology, and Reproductive Sciences; Section Chief, Reproductive Endocrinology and Infertility; Director, Yale Center for Endometrium and Endometriosis and Director of the Yale Center for Reproductive Biology.
"Dr. Taylor has literally defined the field of endometrial stem cells. His fundamental discovery of the bone marrow origin of endometrial cells in humans was one of the major forces behind the now growing field of endometrial stem cell research," said Thomas Ichim, CEO of Medistem. "We strongly believe that Dr. Taylor's deep scientific understanding of biological mechanisms occurring in the endometrium will serve as a foundation for our clinical development programs."
Medistem is the first company to obtain regulatory approvals by the FDA and international regulators for using endometrial derived stem cells, the Endometrial Regenerative Cell (ERC), for the experimental treatment of patients. It appears that one of the major functions of the Endometrial Regenerative Cell in the body is to produce new blood vessels, a process that occurs every month before menstruation. Medistem is focused on harnessing this natural function of the Endometrial Regenerative Cell to produce new blood vessels in the limbs and hearts of patients with poor circulation.
"I am honored to join the Medistem Team, which has a consistent track record of rapid clinical development while concurrently performing in-depth mechanistic analysis behind their products," said Dr. Taylor. "We are eager to take the lessons learned from our animal models and work with the Medistem team to translate them into new medicines."
About Medistem Inc.
Medistem Inc. is a clinical-stage adult stem cell company focused on development of the endometrial regenerative cell (ERC), as a "universal donor" stem cell for treatment of critical limb ischemia and heart failure. The ERC can be purchased for scientific use through Medistem's collaborator, General Biotechnology http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.